SITE001-0267

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-01-10

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-01 (study day 38); relationship: N

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-09 (study day 107); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 148); relationship: not assessed

severe serious assessed

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-03 (study day 193); relationship: not assessed; serious criteria: life-threatening

Data queries

No data queries.